Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -120.78% is in line with its 5-year average of -131.31%, around the middle of its 5-year range (-184.18%–-27.35%).
28.36% above its 12-month average of -168.59%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -26.23%.
RETURN ON ASSETS (ROA)
-120.78%
RETURN ON ASSETS (ROA) AVG TTM
-168.59%
RETURN ON ASSETS (ROA) AVG 3Y
-147.82%
RETURN ON ASSETS (ROA) AVG 5Y
-131.31%
RETURN ON ASSETS (ROA) AVG 10Y
-150.64%
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+28.36%
CURRENT VS 3Y AVG
+18.30%
CURRENT VS 5Y AVG
+8.02%
CURRENT VS 10Y AVG
+19.82%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.27%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
-274.34%
vs the sector median at left
Elicio Therapeutics, Inc.
Market Cap
$35.84M
Return on Assets (ROA)
-120.78%
TTM Avg
-168.59%
3Y Avg
-147.82%
5Y Avg
-131.31%
Market Cap
$35.84M
Return on Assets (ROA)
-110.85%
TTM Avg
-107.44%
3Y Avg
-115.17%
5Y Avg
-101.88%
Market Cap
$35.76M
Return on Assets (ROA)
-103.00%
TTM Avg
-39.81%
3Y Avg
-17.36%
5Y Avg
-12.69%
Market Cap
$35.52M
Return on Assets (ROA)
-60.08%
TTM Avg
-119.59%
3Y Avg
-67.97%
5Y Avg
-67.17%
Market Cap
$36.21M
Return on Assets (ROA)
-277.36%
TTM Avg
-524.61%
3Y Avg
-478.10%
5Y Avg
-316.43%
Market Cap
$34.97M
Return on Assets (ROA)
-136.91%
TTM Avg
-90.70%
3Y Avg
-79.79%
5Y Avg
-214.88%
Market Cap
$34.35M
Return on Assets (ROA)
118.69%
TTM Avg
-31.86%
3Y Avg
-49.56%
5Y Avg
-43.59%
Market Cap
$37.93M
Return on Assets (ROA)
-26.45%
TTM Avg
-127.88%
3Y Avg
-142.31%
5Y Avg
-121.77%
Market Cap
$33.63M
Return on Assets (ROA)
-176.33%
TTM Avg
-88.31%
3Y Avg
-79.12%
5Y Avg
-81.37%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Elicio Therapeutics, Inc. (ELTX) | $35.84M | -120.78% | -168.59% | -147.82% | -131.31% |
| Edesa Biotech, Inc. (EDSA)vs › | $35.84M | -110.85% | -107.44% | -115.17% | -101.88% |
| DocGo Inc. (DCGO)vs › | $35.76M | -103.00% | -39.81% | -17.36% | -12.69% |
| QT Imaging Holdings, Inc. (QTI)vs › | $35.52M | -60.08% | -119.59% | -67.97% | -67.17% |
| EUDA Health Holdings Limited (EUDA)vs › | $36.21M | -277.36% | -524.61% | -478.10% | -316.43% |
| BriaCell Therapeutics Corp. (BCTX)vs › | $34.97M | -136.91% | -90.70% | -79.79% | -214.88% |
| Elutia Inc (ELUT)vs › | $34.35M | 118.69% | -31.86% | -49.56% | -43.59% |
| Incannex Healthcare Limited (IXHL)vs › | $37.93M | -26.45% | -127.88% | -142.31% | -121.77% |
| Scilex Holding Company (SCLX)vs › | $33.63M | -176.33% | -88.31% | -79.12% | -81.37% |
| Grace Therapeutics, Inc. (GRCE)vs › | $33.61M | -42.84% | -15.31% | -31.73% | -29.34% |
ROA
-120.8%
ROE
-476.8%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -153.01% |
| 2024-12-31 | -184.18% |
| 2023-12-31 | -129.65% |
| 2022-12-31 | -124.46% |
| 2021-12-31 | -27.35% |
| 2020-12-31 | -169.19% |
| 2019-12-31 | -342.07% |
| 2018-12-31 | -75.20% |
| 2013-12-31 | 5.71% |
| 2012-12-31 | 2.79% |
